



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Opinion paper

Modulation of Hb-O<sub>2</sub> affinity to improve hypoxemia in COVID-19 patientsSimon Woyke<sup>a</sup>, Simon Rauch<sup>b,c</sup>, Mathias Ströhle<sup>d</sup>, Hannes Gatterer<sup>b,\*</sup><sup>a</sup> Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria<sup>b</sup> Institute of Mountain Emergency Medicine, Eurac Research, Bolzano, Italy<sup>c</sup> Department of Anesthesia and Intensive Care Medicine, "F. Tappeiner" Hospital, Merano, Italy<sup>d</sup> Department of General and Surgical Critical Care Medicine, Medical University of Innsbruck, Innsbruck, Austria

## ARTICLE INFO

## Article history:

Received 15 April 2020

Accepted 24 April 2020

## Keywords:

COVID-19

Nutritional supplement

5-Hydroxymethylfurfural

## SUMMARY

This opinion paper aims at discussing the potential impact of modulating the Hb-O<sub>2</sub> affinity by the nutritional supplement 5-HMF on patients affected by COVID-19. The paper describes the critical role of the oxygen affinity in hypoxemic COVID-19 patients and the potential positive effect of 5-HMF, a compound shown to increase the Hb-O<sub>2</sub> affinity.

© 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

## 1. Introduction and discussion

The oxygen dissociation curve (ODC) describes the dependency of the oxygen saturation on the oxygen partial pressure (PO<sub>2</sub>) [1]. With its sigmoid shape, the curve is subjected to right or left shifts, thereby changing hemoglobin-O<sub>2</sub> affinity. An increase in the partial pressure of carbon dioxide (PCO<sub>2</sub>), in 2,3-diphosphoglycerate (2,3 DPG) and in temperature as well as a decrease in pH lead to a right-shift of the ODC, decreasing oxygen affinity, and vice versa [1,2]. In hypoxemic conditions, a shift of the ODC can significantly alter arterial oxygen saturation (SaO<sub>2</sub>) and consequently arterial oxygen content (CaO<sub>2</sub>). With a PO<sub>2</sub> of 60 mmHg, for instance, SaO<sub>2</sub> may be around 81% [1] at a pH of 7.27 (corresponding to a PCO<sub>2</sub> of 60 mmHg according to Siggaard-Andersen nomogram) and normal body temperature (37 °C), or about 90% at a pH of 7.4, 37 °C body temperature and an PCO<sub>2</sub> of 40 mmHg [3]. Assuming a hemoglobin concentration of 12 g/dl, this corresponds to an increase in CaO<sub>2</sub> from 13.0 to 14.5 ml/dl. Further assuming a cardiac output of 6 l/min, the delivery of oxygen (DO<sub>2</sub>) increases from 780 to 870 ml/min. This increase in DO<sub>2</sub> by augmenting CaO<sub>2</sub> is equivalent to a DO<sub>2</sub> increase by rising cardiac output by approximately 0.7 l/min. This approximates the effect of low-to medium-dose Dobutamine, a commonly used inotrope [4]. The difference in SpO<sub>2</sub> may even widen with lower PO<sub>2</sub>, due to the shape of the ODC, or

changes in body temperature, leading to an even greater effect on DO<sub>2</sub> as outlined before.

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus [5]. The disease is characterized by symptoms of cough and high fever and causes primarily interstitial lung changes and is characterized by a dissociation between relatively well preserved lung mechanics and the severity of hypoxemia [5]. Intrapulmonary ventilation-perfusion mismatch, probably due to impaired hypoxic vasoconstriction, results in hypoxemic respiratory failure [6]. Oxygen administration via face mask or nasal cannula, high-flow-nasal oxygen or non-invasive ventilation are common first-line interventions to improve oxygenation and dyspnea in these patients [5]. In case of persistent hypoxemia or clinical deterioration, endotracheal intubation and invasive ventilation is required. In mechanically ventilated adults with COVID-19, gentle ventilation with low tidal volume is recommended in order not to further damage the lungs [7,8]. Low tidal volume ventilation often results in hypercapnia, which is tolerated to pH levels as low as 7.2 (permissive hypercapnia) [9]. As outlined above, the consequence of the high PCO<sub>2</sub> and increased body temperature is a shift of the ODC to the right, worsening hypoxemia. In these patients, the PO<sub>2</sub> levels are on the steep part of the ODC, so that a small shift of the ODC may have a large effect on the oxygen affinity and thus on SpO<sub>2</sub>. The question arises whether shifting the ODC back to the left would improve oxygenation of COVID-19 patients.

5-hydroxymethylfurfural (5-HMF) is an agent able to shift the oxygen dissociation curve to the left. 5-HMF reduces the P50 (PO<sub>2</sub>

\* Corresponding author.

E-mail address: [hannes.gatterer@eurac.edu](mailto:hannes.gatterer@eurac.edu) (H. Gatterer).

at which 50% of hemoglobin is saturated with oxygen, a parameter indicating the position of the ODC) via allosteric modification of the hemoglobin [10]. Animal studies showed that under severe hypoxia conditions (FiO<sub>2</sub>: 5%), 5-HMF increased hemoglobin affinity, preserved systemic O<sub>2</sub> delivery and partially was able to maintain microvascular oxygenation (i.e., by protecting arteriolar and venular vasodilation and blood flow) [10]. In swine exposed to severe hypoxia, 5-HMF treatment decreased P50, improved SaO<sub>2</sub>, and mitigated increases in pulmonary artery pressure [11]. Moreover, a recent study indicated that the substance might have cardiac protective properties by inhibiting L-type Ca<sup>2+</sup> channels [12]. However, not only in animal and in vitro models beneficial effects were reported. 5-HMF was also found to increase the oxygen affinity in healthy subjects exposed to hypoxia and in sickle cell disease patients [13,14]. Additionally, the combined oral intake of 5-HMF and  $\alpha$ -ketoglutaric acid increased SpO<sub>2</sub> during cycling exercise at 3500 m in healthy subjects [15]. The oral intake of these 2 substances was also shown to reduce oxidative stress, to increase exercise capacity and to reduce ICU and hospitalization time in patients admitted for lung resection [16]. It is important to mention that these substances are available as nutritional supplements and that no relevance for humans concerning carcinogenic and genotoxic effects have been found for 5-HMF supplementation [17].

This makes 5-HMF a potential therapeutic agent for the treatment of hypoxemic COVID-19 patients. By facilitating oxygen loading and increasing SaO<sub>2</sub>, breathing exertion might be reduced. This could delay or even prevent invasive ventilation and hence save valuable intensive care capacity in a crisis like this. In ARDS patients undergoing lung protective ventilation with permissive hypercapnia, a left-shift of the ODC induced by 5-HMF might ameliorate oxygenation by counteracting the hypercapnia effect on the oxygen affinity. On the other hand, a left-shift of the ODC might impair peripheral O<sub>2</sub> unloading, leading to an unchanged cellular oxygen supply despite an increased DO<sub>2</sub>. Even though comparability might be questioned, recent data on hypoxic exercise show that a high O<sub>2</sub>-affinity and hence enhanced oxygen uptake in the lungs, outweighed deficits in peripheral O<sub>2</sub> unloading [2,18]. Additionally, it was reported previously that in hypoxic conditions O<sub>2</sub> unloading from Hb does not require a right-shift of the ODC [19].

In conclusion, the modulation of hemoglobin-oxygen affinity by 5-HMF might be worth investigating as a potential therapeutic target in hypoxemic respiratory failure, e.g. due to COVID-19.

#### Conflict of interest

None.

#### References

- [1] Mairbaurl H, Weber RE. Oxygen transport by hemoglobin. *Comp Physiol* 2012;2:1463–89.
- [2] Dempsey JA. With haemoglobin as with politics - should we shift right or left? *J Physiol* 2020;598:1419–20.
- [3] Mairbaurl H. Red blood cell function in hypoxia at altitude and exercise. *Int J Sports Med* 1994;15:51–63.
- [4] Egstrup M, Gustafsson I, Andersen MJ, Kistorp CN, Schou M, Tuxen CD, et al. Haemodynamic response during low-dose dobutamine infusion in patients with chronic systolic heart failure: comparison of echocardiographic and invasive measurements. *Eur Heart J Cardiovasc Imag* 2012;14:659–67.
- [5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
- [6] Gattinoni L, Coppola S, Cressoni M, Busana M, Chiumello D. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020. <https://doi.org/10.1164/rccm.202003-0817LE>.
- [7] Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.4914>.
- [8] Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Crit Care Med* 2020. <https://doi.org/10.1097/CCM.0000000000004363>.
- [9] Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, et al. Guidelines on the management of acute respiratory distress syndrome. *BMJ Open Respir Res* 2019;6:e000420.
- [10] Yalcin O, Cabrales P. Increased hemoglobin O<sub>2</sub> affinity protects during acute hypoxia. *Am J Physiol Heart Circ Physiol* 2012;303:H271–81.
- [11] Mahon RT, Ciarlone GE, Roney NG, Swift JM. Cardiovascular parameters in a swine model of normobaric hypoxia treated with 5-Hydroxymethyl-2-Furfural (5-HMF). *Front Physiol* 2019;10:395.
- [12] Wolkart G, Schrammel A, Koyani CN, Scherubel S, Zorn-Pauly K, Malle E, et al. Cardioprotective effects of 5-hydroxymethylfurfural mediated by inhibition of L-type Ca(2+) currents. *Br J Pharmacol* 2017;174:3640–53.
- [13] Stern W, Matthews D, McKew JC, Shen J, GJ K. A phase 1, first-in-man, dose-response study of Aes-103 (5-HMF), an anti-sickling, allosteric modifier of hemoglobin oxygen affinity in healthy normal volunteers. *Blood* 2012;120:3210.
- [14] Hannemann A, Cytlak UM, Rees DC, Tewari S, Gibson JS. Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. *J Physiol* 2014;592:4039–49.
- [15] Kossler F, Mair L, Burtscher M, Gatterer H. 5-Hydroxymethylfurfural and alpha-ketoglutaric acid supplementation increases oxygen saturation during prolonged exercise in normobaric hypoxia. *Int J Vitam Nutr Res* 2019;1–6.
- [16] Matzi V, Lindenmann J, Muench A, Greilberger J, Juan H, Wintersteiger R, et al. The impact of preoperative micronutrient supplementation in lung surgery. A prospective randomized trial of oral supplementation of combined alpha-ketoglutaric acid and 5-hydroxymethylfurfural. *Eur J Cardio Thorac Surg* 2007;32:776–82.
- [17] Abraham K, Gurtler R, Berg K, Heinemeyer G, Lampen A, Appel KE. Toxicology and risk assessment of 5-Hydroxymethylfurfural in food. *Mol Nutr Food Res* 2011;55:667–78.
- [18] Dominelli PB, Wiggins CC, Baker SE, Shepherd JRA, Roberts SK, Roy TK, et al. Influence of high affinity haemoglobin on the response to normoxic and hypoxic exercise. *J Physiol* 2020;598:1475–90.
- [19] Calbet JA, Losa-Reyna J, Torres-Peralta R, Rasmussen P, Ponce-Gonzalez JG, Sheel AW, et al. Limitations to oxygen transport and utilization during sprint exercise in humans: evidence for a functional reserve in muscle O<sub>2</sub> diffusing capacity. *J Physiol* 2015;593:4649–64.